Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts
Source: SeekingAlpha
2026-02-10 12:05:31 ET
More on Medpace
- Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript
- Medpace Holdings, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation
- Medpace slumps after Q4 earnings on book-to-bill ratio
- Medpace GAAP EPS of $4.67 beats by $0.48, revenue of $708.5M beats by $17.57M
Read the full article on Seeking Alpha
For further details see:
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts
Medpace Holdings Inc.
NASDAQ: MEDP
MEDP Trading
-0.75% G/L:
$450.99 Last:
111,208 Volume:
$450.52 Open:
MEDP Latest News
February 23, 2026 12:10:00 am
Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates
February 18, 2026 09:00:00 am
Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility
February 16, 2026 01:50:00 pm
Why Big Stock Swings Like Medpace's 55% Jump Usually Have Clear Causes--Not Market Madness
MEDP Stock Data
$12,487,114,097
22,450,074
3.25%
359
N/A
Biotechnology & Life Sciences
Healthcare
US
Cincinnati
